AIQ Global, Inc.

AIQ Solutions develops TRAQinform IQ, a FDA-cleared (510(k) K233998) software medical device for quantitative assessment of treatment response heterogeneity in late-stage cancer patients. The platform analyzes serial radiographic images (PET, CT) to measure change in lesion regions of interest over time, providing oncologists with novel quantitative and spatial information to optimize therapy selection and clinical outcomes. TRAQinform IQ measures intra-patient heterogeneity through metrics such as SUVhetero, which has demonstrated superior prognostication of overall survival compared to standard-of-care methods (RECIST, PERCIST, global SUVpeak, global volume) in retrospective studies of metastatic lung cancer and lymphoma. The software integrates into existing clinical workflows via HIPAA-compliant cloud-based image upload and automated report generation. Primary users are oncologists and clinicians managing patients with metastatic and castration-resistant prostate cancer, metastatic lung cancer, and lymphoma. The company received a new Category III CPT code for lesion heterogeneity assessment. AIQ Solutions operates US offices in Madison, Wisconsin, and an international office in Perth, Australia through the Harry Perkins Institute of Medical Research.